<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-142623</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Adherence to the ESC heart failure treatment guidelines in Spain: ESC heart failure long-term registry</dc:title>
<dc:description xml:lang="en">Introduction and objectives: To estimate the percentage of heart failure patients in Spain that received the European Society of Cardiology recommended treatments, and in those that did not, to determine the reasons why. Methods: The study included 2834 consecutive ambulatory patients with heart failure from 27 Spanish hospitals. We recorded general information, the treatment indicated, and the reasons why it was not prescribed in some cases. In patients who met the criteria to receive a certain drug, true undertreatment was defined as the percentage of patients who, without justification, did not receive the drug. Results: In total, 92.6% of ambulatory patients with low ejection fraction received angiotensin converting enzyme inhibitors or angiotensin receptor blockers, 93.3% beta-blockers, and 74.5% mineralocorticoid receptor antagonists. The true undertreatment rates were 3.4%, 1.8%, and 19.0%, respectively. Target doses were reached in 16.2% of patients receiving angiotensin converting enzyme inhibitors, 23.3% of those with angiotensin receptor blockers, 13.2% of those prescribed beta-blockers, and 23.5% of those with mineralocorticoid receptor antagonists. Among patients who could benefit from ivabradine, 29.1% received this drug. In total, 36% of patients met the criteria for defibrillator implantation and 90% of them had received the device or were scheduled for implantation, whereas 19.6% fulfilled the criteria for resynchronization therapy and 88.0% already had or would soon have the device. In patients who met the criteria, but did not undergo device implantation, the reasons were not cost-related. Conclusions: When justified reasons for not administering heart failure drugs were taken into account, adherence to the guideline recommendations was excellent. Exclusive use of the percentage of treated patients is a poor indicator of the quality of healthcare in heart failure. Measures should be taken to improve the attainment of optimal dosing in each patient (AU)</dc:description>
<dc:creator>Mora-Martín, Manuel de</dc:creator>
<dc:creator>López-Fernández, Silvia</dc:creator>
<dc:creator>García-Pinilla, José Manuel</dc:creator>
<dc:creator>Almenar-Bonet, Luis</dc:creator>
<dc:creator>Fuente-Galán, Luis de la</dc:creator>
<dc:creator>Lara-Padrón, Antonio</dc:creator>
<dc:creator>González-Costello, José</dc:creator>
<dc:creator>Varela-Román, Alfonso</dc:creator>
<dc:creator>Segovia-Cubero, Javier</dc:creator>
<dc:creator>Fernández-Vivancos, Carla</dc:creator>
<dc:creator>Delgado-Jiménez, Juan</dc:creator>
<dc:creator>Sanz-Julve, Marisa</dc:creator>
<dc:creator>Crespo-Leiro, María G</dc:creator>
<dc:creator>Bayes-Genis, Antoni</dc:creator>
<dc:creator>Roig, Eulàlia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos: Estimar la proporción de pacientes con insuficiencia cardiaca atendidos en España que reciben los tratamientos recomendados por la Sociedad Europea de Cardiología y razones de que no los reciban, en su caso. Métodos: Se incluyó a 2.834 pacientes ambulatorios consecutivos con insuficiencia cardiaca de 27 hospitales españoles. Se recogió información general, tratamiento indicado y causas de que no lo recibiera, en su caso. De los pacientes que cumplen criterios para recibir tratamiento, infratratamiento real es la proporción que, sin justificación, no lo recibe. Resultados: El 92,6% de los pacientes ambulatorios con fracción de eyección reducida recibieron inhibidores de la enzima de conversión de la angiotensina o antagonistas del receptor de la angiotensina II; el 93,3%, bloqueadores beta y el 74,5%, antagonistas del receptor mineralocorticoideo. El infratratamiento real es del 3,4, el 1,8 y el 19,0% respectivamente. Alcanzan dosis objetivo de inhibidores de la enzima de conversión de la angiotensina el 16,2% de los pacientes; de antagonistas de los receptores de la angiotensina II, el 23,3%; de bloqueadores beta, el 13,2% y de antagonistas del receptor mineralocorticoideo, el 23,5%. El 29,1% de los pacientes que podrían beneficiarse de ivabradina la reciben; el 36% cumple criterios para implantar desfibrilador; de ellos, el 90% lo tienen ya implantado o programado; las cifras correspondientes en resincronización son el 19,6 y el 88,0%; el porcentaje restante no se debe a causas económicas. Conclusiones: Considerando razones justificadas para no administrar fármacos a estos pacientes, el cumplimiento de las guías es excelente. Utilizar solo la proporción de pacientes tratados es un mal indicador de calidad de la asistencia en insuficiencia cardiaca. Es necesario introducir medidas que mejoren el logro de la dosis óptima para cada paciente(AU)</dc:description>
<dc:source>Rev Esp Cardiol;68(9): 785-793, sept. 2015. ilus, tab</dc:source>
<dc:identifier>ibc-142623</dc:identifier>
<dc:title xml:lang="es">Adecuación en España a las recomendaciones terapéuticas de la guía de la ESC sobre insuficiencia cardiaca: ESC Heart Failure Long-term Registry</dc:title>
<dc:subject>^d6486^s22080</dc:subject>
<dc:subject>^d30763^s22074</dc:subject>
<dc:subject>^d30291</dc:subject>
<dc:subject>^d54223^s22045</dc:subject>
<dc:subject>^d21027^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6486^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>201509</dc:date>
</metadata>
</record>
</ibecs-document>
